Breakthrough cerebral toxoplasmosis in a patient receiving atovaquone prophylaxis after a hematopoietic stem cell transplantation

Orli Megged; Itamar Shalit; Isaac Yaniv; Jerry Stein; Salvador Fisher; Itzhak Levy

doi:10.1111/j.1399-3046.2007.00891.x

Breakthrough cerebral toxoplasmosis in a patient receiving atovaquone prophylaxis after a hematopoietic stem cell transplantation

Pediatr Transplant. 2008 Dec;12(8):902-5. doi: 10.1111/j.1399-3046.2007.00891.x. Epub 2008 Jan 8.

Authors

Orli Megged¹, Itamar Shalit, Isaac Yaniv, Jerry Stein, Salvador Fisher, Itzhak Levy

Affiliation

¹ Infectious Diseases Unit, Schneider Children's Medical Center of Israel, Petah Tiqwa, Israel.

PMID: 18194354
DOI: 10.1111/j.1399-3046.2007.00891.x

Abstract

We describe a case of breakthrough cerebral toxoplasmosis during atovaquone therapy in a child who was intolerant of conventional prophylactic regimens after hematopoietic stem cell transplantation. The available data on the efficacy of atovaquone prophylaxis in Toxoplasma sero-positive stem cell transplant recipients remain limited, and other strategies, such as preemptive strategy using toxoplasma PCR or TMP-SMX desensitization should be considered in this setting.

Publication types

Case Reports

MeSH terms

Anti-Infective Agents / therapeutic use
Atovaquone / therapeutic use*
Child
Encephalitis / complications*
Encephalitis / etiology
Female
Hematopoietic Stem Cell Transplantation / methods*
Humans
Leukemia, Myeloid, Acute / complications
Leukemia, Myeloid, Acute / therapy
Time Factors
Toxoplasmosis, Cerebral / complications*
Toxoplasmosis, Cerebral / etiology
Treatment Outcome
Trimethoprim, Sulfamethoxazole Drug Combination / therapeutic use

Substances

Anti-Infective Agents
Trimethoprim, Sulfamethoxazole Drug Combination
Atovaquone